Journal article
IL-1R2-based biomarker models predict melioidosis mortality independent of clinical data
- Abstract:
-
Introduction: Melioidosis is an often-fatal tropical infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, but few studies have identified promising biomarker candidates to predict outcome.
Methods: In 78 prospectively enrolled patients hospitalized with melioidosis, six candidate protein biomarkers, identified from the literature, were measured in plasma at enrollment. A multi-biomarker model was developed using least absolute shrinkage and selection operator (LASSO) regression, and mortality discrimination was compared to a clinical variable model by receiver operating characteristic curve analysis. Mortality prediction was confirmed in an external validation set of 191 prospectively enrolled patients hospitalized with melioidosis.
Results: LASSO regression selected IL-1R2 and soluble triggering receptor on myeloid cells 1 (sTREM-1) for inclusion in the candidate biomarker model. The areas under the receiver operating characteristic curve (AUC) for mortality discrimination for the IL-1R2 + sTREM-1 model (AUC 0.81, 95% CI 0.72–0.91) as well as for an IL-1R2-only model (AUC 0.78, 95% CI 0.68–0.88) were higher than for a model based on a modified Sequential Organ Failure Assessment (SOFA) score (AUC 0.69, 95% CI 0.56–0.81, p < 0.01, p = 0.03, respectively). In the external validation set, the IL-1R2 + sTREM-1 model (AUC 0.86, 95% CI 0.81–0.92) had superior 28-day mortality discrimination compared to a modified SOFA model (AUC 0.80, 95% CI 0.74–0.86, p < 0.01) and was similar to a model containing IL-1R2 alone (AUC 0.82, 95% CI 0.76–0.88, p = 0.33).
Conclusion: Biomarker models containing IL-1R2 had improved 28-day mortality prediction compared to clinical variable models in melioidosis and may be targets for future, rapid test development.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 542.8KB, Terms of use)
-
- Publisher copy:
- 10.3389/fmed.2023.1211265
Authors
- Publisher:
- Frontiers Media
- Journal:
- Frontiers in Medicine More from this journal
- Volume:
- 10
- Article number:
- 1211265
- Place of publication:
- Switzerland
- Publication date:
- 2023-06-29
- Acceptance date:
- 2023-06-06
- DOI:
- EISSN:
-
2296-858X
- Pmid:
-
37457570
- Language:
-
English
- Keywords:
- Pubs id:
-
1493638
- Local pid:
-
pubs:1493638
- Deposit date:
-
2023-09-20
Terms of use
- Copyright holder:
- Kaewarpai et al.
- Copyright date:
- 2023
- Rights statement:
- © 2023 Kaewarpai, Wright, Yimthin, Phunpang, Dulsuk, Lovelace-Macon, Rerolle, Dow, Hantrakun, Day, Lertmemongkolchai, Limmathurotsakul, West and Chantratita. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record